• Publications
  • Influence
Gelatin–epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief
TLDR
GEH NPs are potentially valuable as a new therapeutic agent delivered in eye drops for treating DES and were successfully produced with high affinity for HCECs and animal eyes.
Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
TLDR
This study indicates that GEH-RGD NPs were successfully developed and synthesized as an inhibitor of vascular endothelial cells with specific targeting capacity and can be used in eyedrops to inhibit angiogenesis in corneal NV mice.
Ocular Drug Delivery: Role of Degradable Polymeric Nanocarriers for Ophthalmic Application
TLDR
This review summarized recent studies on sustained ocular drug/gene delivery and emphasized on the nanocarriers made by biodegradable polymers such as liposome, poly lactic-co-glycolic acid (PLGA), chitosan, and gelatin.
Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products
TLDR
This manuscript seeks to provide relevant background information on the management of dry eye syndrome and on the increasing role that various types of SED or platelet lysates, from autologous or allogeneic origins, are playing in the improved therapeutic management of this pathology.
Nanotechnology in the regulation of stem cell behavior
TLDR
This work summarizes recent studies on nanotechnology with applications to stem cell biology, including the regulation of stem cell adhesion, growth, differentiation, tracking and imaging, and the interactions of nanomaterials with stem cells.
Development of Kaempferol-Loaded Gelatin Nanoparticles for the Treatment of Corneal Neovascularization in Mice
TLDR
The mice’s eyes with corneal NV treated by eye drops containing GNP-KA once daily for 7 days had better therapeutic effects with less vessels in-growths in the cornea, compared to the KA solution group by reducing the production of MMP and VEGF in the Cornea.
...
...